

Who we are

Teva Canada Innovation (TCI) is a branded, innovative specialty medicines company.

We are guided by a desire to enable people to have greater control over their health and live life to its fullest potential. This is the motivation behind everything we do, and we apply our expertise and passion in the pursuit of this goal.

TCI is a subsidiary of Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day.

Mission & Vision

Our mission is to introduce new, innovative health care solutions tailored to the unique needs of Canadians affected by health issues in the central nervous system, pain, respiratory and oncology therapeutic areas.

We attribute TCI's success to its focus on the patient, its caring, highperformance work environment, and to our products that make a difference in the lives of those we serve.

— How are we pursuing our goal?

- By creating a holistic ecosystem of care, including novel delivery systems and first class patient support programs, we are helping our patients to take control of their health, and delivering better outcomes for healthcare professionals.
- Through our commitment to enabling access to medication, by sharing the fruits of our innovation and expertise.
- By facilitating partnerships to accelerate the delivery of medicines that address healthcare needs, and help ensure the sustainability of Canada's healthcare system.

Our Values: Improving health, making people feel better



— Our Focus

TCI offers innovative pharmaceuticals and healthcare solutions in the following therapeutic areas:

- Central Nervous System (CNS) & Pain
- Respiratory
- Oncology
- Women's Health*

*TCI has established additional partnerships with other Canadian pharmaceutical companies in this area.

Our Products

- ALERTEC®
- AZILECT®
- COPAXONE®
- FROVA®
- CINQAIR ™
- ─ FENTORA™
- DIVIGEL®
- LOESTRIN®
- MINESTRIN®



Innovation at TCI

Innovation is central to our culture and strategy.

For TCI, innovation means developing safe, effective and well-tolerated products. It means promoting new approaches and pioneering solutions to fight disease.

Above all, it means creating an ecosystem of care for those affected by those diseases because for us, the quality of life and health of our patients go hand in hand.

TCI's domestic growth strategy addresses the rapid pace of change in health markets, and the increasing trend towards patient-centred care and personalized medicine.

Capabilities

TCI has access to significant support and resources and is uniquely placed to leverage the strengths, experience and assets of Teva Pharmaceuticals Industries Ltd., a global leader in generics production.



TCI, a partner of choice:

- A highly collaborative organization deeply committed to improving patient health
- Strong commercialization abilities through leadership in regulatory, market access and sales capabilities, in addition to highly rated patient support programs (PSPs)
- Organizational structure that enhances communication and drives results
- Retaining a proven track record for success
- Open to a variety of deal structures

A partner of choice to companies seeking commercialization support and/or in-licensing opportunities, TCI remains in search of new collaborators to join us on our journey.

For more information on becoming a partner please contact TCI.partnership@tevapharm.com



Patient Support Programs

Our patient support programs exemplify our unfailing commitment to our patients. The reputation of these programs is a testament to the quality, neutrality and experience of our nurse consultants.

Shared Solutions® is a unique and personalized support program available to anyone touched by multiples sclerosis (MS) (but not limited to any specific MS therapy patients) including family members, friends, caregivers and healthcare professionals.

Teva Support Solutions® (TSS) is a comprehensive program that will provide personalized support, training and education to healthcare providers and patients who have been prescribed CINQAIRTM.

